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This study demonstrates that in vitro incubation of isolated rat brain mitochondria with recombi-
nant human a-synuclein leads to dose-dependent loss of mitochondrial transmembrane potential
and phosphorylation capacity. However, a-synuclein does not seem to have any signiﬁcant effect
on the activities of respiratory chain complexes under similar conditions of incubation suggesting
that the former may impair mitochondrial bioenergetics by direct effect on mitochondrial mem-
branes. Moreover, the recombinant wild type a-synuclein and different mutant forms (A30P,
A53T and E46K) have essentially similar effects on rat brain isolated mitochondria. The results are
signiﬁcant in view of the fact that a-synucleinopathy is involved in the pathogenesis of Parkinson’s
disease.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
a-Synuclein is a brain-enriched neuron speciﬁc protein that
binds to synaptic vesicles, synaptosome and synthetic phospho-
lipid membranes and this 140 amino acid protein is a major com-
ponent of Lewy body, which is seen in degenerating dopaminergic
neurons in sporadic PD [1,2]. The mutations A30P, A53T and E46K
of a-synuclein have been identiﬁed in early onset familial PD pa-
tients [2,3]. Lewy bodies have also been identiﬁed in the substantia
nigra of such patients [2,3].
Several important observations have implicated the involve-
ment of a-synuclein in the pathogenesis of PD [4]. Over expres-
sion of human a-synuclein in transgenic mice, rats and
drosophila leads to degeneration of dopaminergic neurons and
characteristics motor deﬁcit and likewise the triplication of the
a-synuclein locus causes PD in some individuals [5–8]. Over
expression of a-synuclein in some dopaminergic cell lines leads
to cell death especially after exposure to dopamine (DA) or otherchemical Societies. Published by E
f Biochemistry, Institute of
Building (4th Floor), 244B,
91 33 22234659.
K. Banerjee), sasanka_c54@toxins [9,10]. However the mechanism of toxicity of a-synuclein
in dopaminergic cells is neither clearly established nor is it
known with certainty whether the monomeric, oligomeric or
the ﬁbrillar forms of a-synuclein are the actual toxic species
[11]. Since mitochondrial dysfunction is considered to play a cen-
tral role in the pathogenesis of PD, several studies have attempted
to investigate the possible toxic effect of a-synuclein on mito-
chondria. The accumulation of wild type or mutant a-synuclein
in the mitochondria of human dopaminergic neurons causes de-
creased complex I activity and an increase in ROS production
[12]. In transgenic mice over expressing a-synuclein, the toxicity
of MPTP is enhanced leading to varied forms of mitochondrial
abnormalities [13]. Moreover, a-synuclein can bind to mitochon-
drial cytochrome c oxidase, and in GT1-7 cells over expressing a-
synuclein causes different structural and functional alterations of
the mitochondria [14,15]. However, the detailed mechanisms of
a-synuclein mitochondria interaction and possible impairment
of mitochondrial oxidative phosphorylation are not established.
The present study has attempted to identify, in a systematic man-
ner, the effects of a-synuclein (wild type and three mutant forms)
on isolated rat brain mitochondrial electron transport chain activ-
ity, transmembrane potential and phosphorylation capacity
in vitro which may have implications in the pathogenesis of
sporadic PD.lsevier B.V. All rights reserved.
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2.1. Animals
Albino rats of Charles–Foster strain maintained as per the regu-
lations and guidelines of the Animal Ethical Committee of the Insti-
tute have been used in this study.
2.2. Puriﬁcation of a-synuclein
Recombinant a-synuclein (wild type, A30P, A53T and E46K)
were obtained by puriﬁcation of a-synuclein from over expressing
Escherichia coli BL21 (DE3). The puriﬁcations of wild type a-synuc-
lein and its familial mutants were performed as described previ-
ously for wild type a-synuclein [16,17]. This involved sonication
of expression cell pellet followed by centrifugation to obtain solu-
ble lysate, acid precipitation of cell lysate, and ﬁnal puriﬁcation by
successive anion exchange and size exclusion chromatography.
The puriﬁed protein was extensively dialyzed against ultrapure
water to remove the salts and buffer components and lyophilized.
The purity of the protein was determined by SDS–PAGE analysis
and mass spectrometry. The protein concentration was determined
using the 280 nm extinction coefﬁcient of 5120 M1 cm1. a-Syn-
uclein was dissolved in autoclaved deionized water and stored at
20 C without any preservative.
2.3. Isolation of rat brain mitochondria
Rat brain mitochondria were isolated by a method based on dif-
ferential centrifugation with digitonin treatment as published ear-
lier [18,19]. The ﬁnal mitochondrial pellet was suspended in
isotonic buffer A (145 mM KCl, 50 mM sucrose, 1 mM EGTA,
1 mM magnesium chloride, 10 mM phosphate buffer, pH 7.4) and
used immediately for the experiments related to measurement of
membrane potential and phosphorylation capacity. For the mea-
surement of activity of respiratory complexes, the mitochondrial
pellet was suspended in 50 mM phosphate buffer, pH 7.4, stored
at 20 C and used within 3 days.
2.4. Incubation of rat brain mitochondria with a-synuclein
An aliquot of rat brain mitochondria (protein content approx.
150–225 lg) was incubated in isotonic buffer A for measurement
of transmembrane potential and phosphorylation capacity or in
50 mM phosphate buffer for assay of respiratory chain complexes
with or without a-synuclein (5–40 lM) for up to 2 h in a total vol-
ume of 60 ll at 37 C. At the end of the incubation the mitochon-
dria were pelleted out and washed with an excess of ice cold
incubation buffer and ﬁnally resuspended in the same buffer. An
aliquot of resuspended mitochondria was then used for the mea-
surement of transmembrane potential, phosphate utilization, ATP
synthesis and activities of respiratory complexes.
2.5. Measurement of transmembrane potential of rat brain
mitochondria
Mitochondrial transmembrane potential was measured by
using a mitochondrial membrane potential sensitive carbocyanine
dye JC-1 (5,50,6,60-tetrachloro-1,10,3,30-tetraethyl-benzamidazolo-
carbocyanine iodide, Alexis Biochemicals, USA). When excited at
490 nm, the monomeric form of JC-1 had an emission maximum
at 527 nm, but the aggregated form (J-aggregates) showed an
emission maximum at 590 nm [20]. When isolated mitochondria
were incubated with JC-1, the dye accumulated within mitochon-
dria driven by the negative transmembrane potential and formedconcentration dependent J-aggregates [21]. The excess monomeric
dye in the medium could be removed by several washings and the
red ﬂuorescence of intra mitochondrial J-aggregates measured at
590 nm. Brieﬂy, an aliquot of mitochondria (control or a-synuclein
treated) was incubated at 37 C for 30 min in isotonic buffer A con-
taining 10 mM pyruvate, 10 mM succinate and 1 mM ADP in the
presence of 5 lM JC-1. At the end of the incubation, the dye loaded
mitochondria were collected by centrifugation, washed extensively
with isotonic buffer A to remove the excess dye and then resus-
pended in the same buffer in appropriate dilution, followed by
the measurement of ﬂuorescence intensity (kex 490 nm, kem
590 nm) in a JASCO (FP 6500) spectroﬂuorometer as published ear-
lier [21].
2.6. Measurement of phosphorylation capacity (inorganic phosphate
utilization and ATP synthesis) of rat brain mitochondria
2.6.1. Measurement of phosphate utilization of mitochondria
Mitochondrial phosphate utilization was assayed following the
method published earlier [22]. Brieﬂy, in a total volume of 250 ll,
an aliquot of 25 ll mitochondrial suspension from control or a-
synuclein treated mitochondria was diluted into a medium con-
taining 125 mM KCl, 75 mM sucrose, 0.1 mM EGTA, 1 mM MgCl2,
10 mM HEPES, 2 mM phosphate, 0.3% bovine serum albumin (Sig-
ma), 0.5 mM ADP (Sigma), 5 mM pyruvate, 10 mM succinate and
10 mM glucose, followed by the immediate addition of 5 units of
hexokinase (Sigma) and the incubation was continued at 37 C
for 30 min. The incubation was terminated by the addition of 5%
ice cold trichloroacetic (TCA) acid and the amount of inorganic
phosphate estimated spectrophotometrically. A 0 min sample
was also assayed for inorganic phosphate content where hexoki-
nase addition was immediately followed by the treatment with
5% ice cold TCA. Glucose and hexokinase in the reaction mixture
acted as a trap for ATP to maintain the level of ADP in the system
as also to prevent the release of free inorganic phosphate from ATP
by the action of various phosphatases.
2.6.2. Measurement of ATP synthesis by mitochondria
ATP content was measured in aliquots of mitochondrial suspen-
sion by a luminometric assay based on luciferin–luciferase reaction
[23] using a commercial kit (Sigma). Each sample of mitochondrial
suspension (control or a-synuclein treated) was analysed for ATP
content at 0 min and then after an incubation for 15 min at 37 C
in isotonic buffer A containing 10 mM pyruvate, 10 mM succinate
and 0.5 mM ADP and the difference expressed as n moles of ATP
generated/min/mg protein. Mitochondrial membranes were lysed
in a buffer containing tris, 10 mM and Triton X-100 (0.05%) before
adding to the luciferin–luciferase assay mixture for ATP measure-
ment. An appropriate blanks was kept for each sample and the cal-
ibration curves drawn for ATP standards for each set of
experiments with corrections wherever necessary because of
added respiratory substrates and ADP. Further, it was veriﬁed that
0.05% Triton X-100 did not affect the luminometric assay of ATP.
2.7. Measurement of respiratory chain activity of brain mitochondria
after DA exposure
The activity of NADH-ferricyanide reductase (complex I) was
assayed by using ferricyanide as the electron acceptor in a system
containing 0.17 mM NADH (SRL, India), 0.6 mM ferricyanide, and
Triton X-100 (0.1% v/v) in 50 mM phosphate buffer, pH 7.4 at
30 C [19,24]. The reaction was initiated by the addition of mito-
chondrial suspension (10–30 lg protein) to the sample cuvette
and the rate of oxidation of NADH was measured by the decrease
in absorbance at 340 nm.
Fig. 2. Dose-dependent effect of a-synuclein on mitochondrial phosphate utiliza-
tion. Rat brain mitochondria were incubated in the presence of recombinant human
a-synuclein (5–40 lM) for 2 h at 37 C followed by the measurement of mitochon-
drial utilization of inorganic phosphate as described in Section 2. Values are the
means ± S.E.M. of eight observations. Statistical signiﬁcance was calculated by
Student’s ‘t’ test paired. DP < 0.005, #P < 0.001 vs. control.
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III) was assayed by following the succinate supported reduction
of ferricytochrome c to ferrocytochrome c at 550 nm in an assay
mixture containing 100 mM phosphate buffer, 2 mM succinate,
1 mM KCN, 0.3 mM EDTA (Sigma) and 1.2 mg/ml cytochrome c
(Sigma) in a total volume of 1 ml [25]. The reaction was initiated
by adding mitochondrial suspension (10–30 lg) in the sample cuv-
ette. The same assay was repeated with (10 lM) antimycin (Sigma)
to determine the inhibitor sensitive rate.
The activity of cytochrome c oxidase (complex IV) was assayed
by measuring the rate of decrease of absorbance at 550 nm at room
temperature following the oxidation of reduced cytochrome c
(50 lM) in 10 mM phosphate buffer pH 7.4 [26]. Ferricyanide
(1 mM) was added to oxidize ferrocytochrome c in the blank cuv-
ette and the reaction initiated in the sample cuvette by the addi-
tion of mitochondrial suspension (10–30 lg). The activity of the
enzyme was calculated from the ﬁrst order rate constant.
2.8. Protein estimation
The protein was estimated after solubilizing the membranes in
1% SDS by Lowry’s method [27].
2.9. Statistical analysis
Statistical analysis was done by Student’s ‘t’ test, paired. Each
experiment was repeated several times and the values expressed
as the means ± S.E.M.
3. Results
3.1. Effects of a-synuclein on mitochondrial membrane potential and
phosphorylation capacity
The data presented in Fig. 1 show a dose-dependent (5–40 lM)
loss of mitochondrial membrane potential in the presence of
increasing concentrations of wild type a-synuclein with maximum
inhibition observed around 20 lM. A maximum loss of approxi-
mately 25% of J-aggregates ﬂuorescence was noticed in a-synuc-
lein treated mitochondria compared to that in control (Fig. 1).Fig. 1. a-Synuclein causes loss of mitochondrial transmembrane potential in a
dose-dependent manner. Rat brain mitochondria were incubated with varying
concentrations of recombinant a-synuclein (5–40 lM) at 37 C for 2 h followed by
the measurement of mitochondrial transmembrane potential using JC-1 as detailed
in Section 2. Values (arbitrary ﬂuorescence unit normalized to 100 lg protein) are
the means ± S.E.M. of eight observations. Statistically signiﬁcant, WP < 0.01,
*P < 0.05, DP < 0.005 vs. control, Student’s ‘t’ test, paired.When rat brain mitochondria were incubated with recombinant
wild type a-synuclein (5–40 lM) for 2 h at 37 C, a remarkable de-
crease in mitochondrial utilization of inorganic phosphate was ob-
served (Fig. 2). This decrease in phosphate utilization was also
dose-dependent and progressive up to 40 lM and a maximum loss
of 55% compared to that in control could be detected (Fig. 2). ATP
synthesis was also decreased by nearly 25% compared to that in
control when rat brain mitochondria were treated with 20 lM of
a-synuclein for 2 h (Fig. 3).
3.2. Effects of mutant a-synucleins on membrane potential and
phosphorylation capacity of brain mitochondria during in vitro
incubation
When rat brain mitochondria were incubated with three differ-
ent familial PD associated mutant a-synuclein (A30P, A53T and
E46K) for 2 h at 37 C, a clear decrease in transmembrane potentialFig. 3. a-Synuclein impairs ATP synthesis in rat brain mitochondria. Isolated
mitochondria from rat brain were exposed to 20 lM recombinant wild and mutant
a-synucleins for 2 h at 37 C followed by the measurement of ATP synthesis rate
during a further 15 min incubation with respiratory substrates and ADP as detailed
in Section 2. Values are the means ± S.E.M. of four observations. Statistically
signiﬁcant, *P < 0.001, #P < 0.005 DP < 0.01 vs. control, Student’s ‘t’ test, paired.
Fig. 4. a-Synuclein familial mutants induced impairment of mitochondrial trans-
membrane potential and phosphate utilization. Rat brain mitochondria were
incubated at 37 C for 2 h with 20 lM of wild or mutant (A30P, A53T and E46K) a-
synuclein. Mitochondrial transmembrane potential (A) or phosphorylation capacity
(B) was measured as described in Section 2. Values are the means ± S.E.M. of eight
observations. Statistical signiﬁcance was calculated by Student’s ‘t’ test paired.
WP < 0.01, *P < 0.05, DP < 0.005 vs. control.
Fig. 5. Effect of wild type and mutant a-synuclein on mitochondrial electron
transport chain activity. Mitochondria isolated from rat brain were incubated at
37 C for 2 h with 20 lM of wild or mutant (A30P, A53T and E46K) a-synuclein
followed by the measurement of the activities of complex I (A), complex II–III (B)
and complex IV (C) as detailed in the text. Values given are the means ± S.E.M. of six
observations.
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was observed. However, there was no signiﬁcant difference be-
tween the mutants and wild type a-synuclein, as they all inhibited
these mitochondrial functional parameters to a similar extent. The
phosphate utilization of control mitochondrial preparations in dif-
ferent sets of experiments varied from 210 to 325 nmoles of inor-
ganic phosphate used/min/mg protein. Further, ATP synthesis rate
as measured here represented the apparent rate as ATP was likely
to be converted to other high energy phosphate compounds or uti-
lized for other purposes during the measurement period of 15 min.
3.3. a-Synuclein effects on respiratory chain complexes of rat brain
mitochondria
When rat brain mitochondria were incubated with 20 lM a-
synuclein (wild type or mutant varieties) for 2 h at 37 C, no statis-
tically signiﬁcant change in the activities of complex I (Fig. 5A),
complex II–III (Fig. 5B) and complex IV was observed (Fig. 5C).
4. Discussion
Our results have demonstrated a direct toxic action of a-synuc-
lein on isolated mitochondria during in vitro incubation. The toxicactions of a-synuclein on mitochondria include the loss of mito-
chondrial transmembrane potential with an associated decrease
in the phosphorylation capacity as revealed by a loss of phosphate
utilization and ATP synthesis. It is interesting that a-synuclein un-
der our experimental conditions has no effect on the activities of
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previous studies where complex I inhibition by a-synuclein has
been reported in human dopaminergic neurons [12]. The fact that
a-synuclein in our study has shown an inhibitory effect on mito-
chondrial transmembrane potential and phosphorylation capacity
without affecting the activities of mitochondrial complexes clearly
indicates that a-synuclein has a direct action on mitochondrial
membrane. Speciﬁc interaction of a-synuclein with mitochondria
induces a conformational change in a-synuclein, from a ‘close’ con-
formation to an ‘open’ conformation upon binding to the mem-
brane [28]. Several proteins including a-synuclein have further
been shown to gain entry in to mitochondria through import
receptors present in outer and inner membranes of the organelle
[12,29]. Such mechanisms presumably are also involved in our
experimental system when a-synuclein interacts with intact mito-
chondria to alter membrane potential, phosphate utilization and
ATP synthesis. Different types of ion channels exist in the inner
membrane of mitochondria which can be modulated by diverse
agents like fatty acids, divalent cations, thiols, nucleotides, signal
peptide and palmitoyl coA, leading to a loss of transmembrane po-
tential [30]. It is plausible that a-synuclein activates some of these
channels causing dissipation of electrochemical gradient and mito-
chondrial membrane depolarization. On the other hand, a-synuc-
lein is known to bind to synthetic phospholipid bilayers as well
as plasma membrane, synaptic vesicles etc. [2,31,32]. It has been
proposed that binding of a-synuclein to lipid bilayers can lead to
oligomerization of the protein and subsequent disruption of the li-
pid membrane or channel formation within the lipid bilayer [33]. It
may be speculated that a-synuclein interacts in a similar fashion
with the mitochondrial membrane. This would cause disruption
or pore formation and subsequent loss of transmembrane potential
because of the entry of cations from outside into the mitochondria.
The decrease in phosphorylation capacity of mitochondria in the
presence of a-synuclein may be a direct consequence of mitochon-
drial membrane potential loss. However, a-synuclein may have
other effects on mitochondrial phosphorylation since the extent
of inhibition of phosphate utilization is apparently more pro-
nounced and progressive compared to alterations in membrane
potential.
Our experiments have been conducted with a-synuclein con-
centration in the range of 5–40 lM and the effects observed are
moderate, reaching a plateau above 20 lM a-synuclein. The phys-
iological concentration of a-synuclein in brain has been estimated
to be around 1 lM [34] and therefore the toxic action of a-synuc-
lein on the mitochondria under normal conditions may not be
apparent. However, under conditions in which over expression of
a-synuclein occurs or when mitochondrial functions are already
compromised within neurons, the toxic effects of a-synuclein on
mitochondria such as membrane depolarization and diminished
phosphorylation capacity with resultant ATP depletion can trigger
apoptotic or necrotic neuronal death. It is interesting to point out
that over expression of a-synuclein in PC12 cells or exposure of
such cells to 10 lM extra-cellular concentration of a-synuclein
can induce apoptotic neuronal death through bax over expression,
cytochrome c release and caspase activation [34]. The direct toxic
effects of a-synuclein on mitochondria as demonstrated in this
study might have contributed to apoptotic death of PC12 cells pre-
sented in the above study [34]. Furthermore, dopaminergic neu-
rons over expressing a-synuclein undergo apoptotic cell death
following exposure to DA or other agents like, rotenone and MPTP
in cell culture models or experimental animals [7,10,13,35]. Dopa-
mine and its oxidized products produce varied forms of mitochon-
drial toxicity in isolated mitochondrial preparations, cultured cells
or in animal models [19]. It is conceivable that in the scenario
existing within nigral dopaminergic neurons mitochondrial func-
tion will remain compromised because of toxic actions of DA orits oxidation products and a-synuclein especially when over ex-
pressed will further aggravate the situation. The up regulation of
a-synuclein gene expression leading to 10 fold increase in the level
of a-synuclein in substantia nigra of sporadic PD subjects has been
reported [36]. Thus the results of the present study are extremely
relevant to the pathogenesis of sporadic PD in linking together the
toxic effects of DA and a-synuclein in the nigral neurons.
Several forms of early onset familial PD are associated with
mutations in a-synuclein gene and we assumed that mutant forms
of a-synuclein would lead to enhanced toxic effects on isolated
mitochondria. Contrary to our expectation, the present results
clearly demonstrate that, wild type and mutant forms of a-synuc-
lein do not differ in a detectable way in their toxic actions on rat
brain mitochondria. However, some studies indicate that mutant
forms of a-synuclein are resistant to proteasomal degradation
which is a major route of clearance of a-synuclein from the neu-
rons and this phenomenon is likely to cause an elevation of intra
neuronal level of a-synuclein which in turn can lead to accelerated
death of dopaminergic neurons and early onset familial PD.Acknowledgments
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